EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, IRD: Opus Genetics Inc

28 Oct 25 18:26
LAST:

1.930

CHANGE:
 0.07		OPEN:
2.000		HIGH:
2.018		ASK:
0.000		VOLUME:
303.6K
CHG(%):
3.50		PREV:
2.000		LOW:
1.900		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
28 Oct 252.0002.0181.9001.930303.6K
27 Oct 251.9702.0201.9502.000342.3K
24 Oct 251.9802.0001.9101.990242.7K
23 Oct 251.9802.0001.9002.000274.9K
22 Oct 252.0102.0301.8901.950357.8K
21 Oct 251.9802.0401.9002.010390.5K
20 Oct 251.9302.0001.9051.980324.2K
17 Oct 251.9902.0251.8591.870367.9K
16 Oct 252.0102.0901.9802.010585.2K
15 Oct 252.0202.0351.9002.000291.2K

COMPANY PROFILE

Name:Opus Genetics Inc
About:Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.
Sector:Healthcare
Industry:Biotechnology
Address:8 Davis Drive, Durham, NC, United States, 27709
Website:https://opusgtx.com
CIK:0001877769
ISIN:US67577R1023
FIGI:BBG000BT34Q3

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:1.972.3%
MA10:1.972.3%
MA20:1.961.7%
MA50:1.6219.2%
MA100:1.3443.8%
MA200:1.1764.6%
STO9:27.27
STO14:27.27
RSI14:40.32
WPR14:-57.14
MTM14:-0.06
ROC14:-0.03 
ATR:0.12 
Week High:2.045.7%
Week Low:1.892.1%
Month High:2.1611.9%
Month Low:1.5064.6%
Year High:2.1611.9%
Year Low:0.65196.9%

RECENT SPLITS

Date Ratio
06 Nov 20201-4
12 Apr 20191-12
05 May 20171-10